X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.
Lead Product(s): Perillyl Alcohol
Therapeutic Area: Oncology Product Name: NEO100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeOnc Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
